Mapping Functions in Health-Related Quality of Life

Medical Decision Making

Volumn 35, Issue 7, 2015, Pages 912-926

  Young, Tracey A ^a   Mukuria, Clara ^a   Rowen, Donna ^a   Brazier, John E ^a   Longworth, Louise ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

cancer; EORTC QLQ C30; EQ 5D 3L; FACT G; health related quality of life; mapping functions

Indexed keywords

HUMAN; NEOPLASM; PATHOPHYSIOLOGY; QUALITY OF LIFE;

HUMANS; NEOPLASMS; QUALITY OF LIFE;

EID: 84941790437     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X15587497     Document Type: Article

References (40)

1. National Institute of Health and Care Excellence (NICE). NICE Guide to the Methods of Technology Appraisal. London: NICE; 2013.
2. Longworth L, Yang Y, Young T, Hernandez Alva M, Mukuria C, Rowen D, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: systematic review, statistical modelling and survey. Health Tech Assessment. 2014; 18: 9.
3. Brazier JE, Yang Y, Tsuchiya A, Rowen DL,. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010; 11 (2): 215-25.
4. Cheung YB, Thumboo J, Gao F, Ng GY, Pang G, Koo WH, et al. Mapping the English and Chinese versions of the Functional Assessment of Cancer Therapy€General to the EQ-5D Utility Index. Value in Health. 2009; 12 (2): 371-6.
5. McKenzie L, van der Pol M,. Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data. Value in Health. 2009; 12 (1): 167-71.
6. Khan I, Morris S,. A non-linear beta-binomial regression model for mapping EORTC QLQ-C30 to the EQ-5D-3L in lung cancer patients; a comparison with existing approaches. Health Qual Life Outcomes. 2014; 12: 163.
7. Proskorovsky I, Lewis P, Williams CD, Jordan K, Kyriakou C, Ishak J, et al. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma. Health Qual Life Outcomes. 2014; 12 (1): 35.
8. Kontodimopoulos N, Aletras VH, Paliouras D, Niakas D,. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Value in Health. 2009; 12 (8): 1151-7.
9. Wu EQ, Mulani P, Farrell MH, Sleep D,. Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. Value in Health. 2007; 10 (5): 408-14.
10. Pickard AS, Shaw JW, Lin H-W, Trask PC, Aaronson N, Lee TA, et al. A patient-based utility measure of health for clinical trials of cancer therapy based on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire. Value in Health. 2009; 12 (6): 977-88.
11. Crott R, Briggs A,. Mapping the QLQ-C30 Quality of Life Cancer Questionnaire to EQ-5D patient preferences. Eur J Health Econ. 2010; 11 (4): 427-34.
12. Crott R, Versteegh M, Uyl-de-Groot C,. An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences. Qual Life Res. 2012 29.
13. Versteegh M, Leunis A, Luime JJ, Boggild M, Uyl-de Groot CA, Stolk EA,. Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Med Decis Making. 2012; 32 (4): 554-68.
14. Versteegh M, Rowen D, Brazier J, Stolk E,. Mapping onto EQ-5D for patients in poor health. Health Qual Life Outcomes. 2010; 8 (1): 141.
15. Rowen D, Young T, Brazier J, Gaugris S,. Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer. Value in Health. 2012; 15 (8): 1059-68.
16. Kim EJ, Ko SK, Kang HY,. Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients. Qual Life Res. 2012 Sep; 21 (7): 1193-203.
17. Jang RW, Isogai PK, Mittmann N, Bradbury PA, Shepherd FA, Feld R, et al. Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer. J Thorac Oncol. 2010; 5 (12): 1953-7.
18. Kim SH, Jo MW, Kim HJ, Ahn JH,. Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients. Health Qual Life Outcomes. 2012; 10: 151.
19. Brooks R,. EuroQol: the current state of play. Health Policy. 1996; 37 (1): 53-72.
20. Dolan P,. Modeling valuations for EuroQol health states. Med Care. 1997 1; 35 (11): 1095-108.
21. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993 1; 11 (3): 570-9.
22. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 3; 85 (5): 365-76.
23. Pickard AS, De Leon MC, Kohlmann T, Cella D, Rosenbloom S,. Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care. 2007; 45 (3).
24. Greipp PR, Miguel JS, Durie BGM, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005 20; 23 (15): 3412-20.
25. Brazier J, Yang Y, Tsuchiya A, Rowen D,. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010; 11 (2): 215-25.
26. Dakin H,. Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database. Health Qual Life Outcomes. 2013; 11 (1): 151.
27. Huang IC, Frangakis C, Atkinson MJ, Willke RJ, Leite WL, Vogel WB, et al. Addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease. Health Serv Res. 2008; 43 (1 Pt 1): 327-39.
28. Royston P, Sauerbrei W,. Multivariable modeling with cubic regression splines: a principled approach. Stata J. 2007; 7 (1): 45-70.
29. Gray AM, Rivero-Arias O, Clarke PM,. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Making. 2006; 26 (1): 18-29.
30. Rivero-Arias O, Ouellet M, Gray A, Wolstenholme J, Rothwell PM, Luengo-Fernandez R,. Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med Decis Making. 2010; 30 (3): 341-54.
31. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Amer J Clin Oncol. 1982; 5 (6).
32. Steyerberg EW, Eijkemans MJC, Harrell FE, Habbema JD,. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Statist Med. 2000; 19 (8): 1059-79.
33. StataCorp. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP; 2011.
34. Rowen D, Brazier J, Roberts J,. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes. 2009; 7: 27.
35. Sullivan PW, Ghushchyan V,. Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample. Med Decis Making. 2006; 26 (4): 401-9.
36. Powell JL,. Least absolute deviations estimation for the censored regression model. J Econometrics. 1984; 25 (3): 303-25.
37. Sullivan PW,. Are utilities bounded at 1.0? implications for statistical analysis and scale development. Med Decis Making. 2011; 31 (6): 787-9.
38. Pullenayegum EM, Tarride JE, Xie F, OReilly D,. Calculating utility decrements associated with an adverse event marginal Tobit and CLAD coefficients should be used with caution. Med Decis Making. 2011; 31 (6): 790-9.
39. Arnold D, Rowen D, Versteegh M, Morley A, Hooper C, Maskell N,. Testing mapping algorithms of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma. Health Qual Life Outcomes (In Press).
40. Longworth L, Rowen D,. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value in Health. 2013; 16: 202-10.